{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:23:18Z","timestamp":1787289798883,"version":"build-2736575974"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The prevalence of type 2 diabetes mellitus (T2DM) with concurrent Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) is high. However, simple, efficient and non-invasive diagnostic tools based on routine serological indicators are lacking. This study aims to construct and validate a simple diagnostic model using routine serological indicators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective case-control study is conducted, enrolling 470 patients with T2DM. They are randomly stratified into a training set and a validation set at a 7:3 ratio. Independent predictive factors are identified using univariate and multivariate logistic regression. Diagnostic performance is assessed via receiver operating characteristic (ROC) curves. A nomogram diagnostic model is constructed and evaluated using ROC curves, calibration curves and decision curve analysis. For external validation, an additional 300 T2DM patients are recruited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Body mass index (BMI), fasting C-peptide, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), urea and alanine aminotransferase (ALT) are independent predictors of comorbid T2DM and MASLD. The area under the curve (AUC) of this model in the training set, internal validation set and external validation set is 0.921, 0.913 and 0.830, respectively. The calibration curve closely approximates the ideal diagonal line and decision curve analysis (DCA) demonstrates significant clinical net benefit across a broad range of threshold probabilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This model enables high-precision diagnosis of T2DM with MASLD using routinely available serological indicators, avoiding invasive procedures and exhibiting strong potential for clinical translation. Future studies should validate its generalizability in multicenter prospective cohorts to promote its use as a routine screening tool for MASLD in T2DM patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1891690","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:23:03Z","timestamp":1787286183000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction and validation of a diagnostic model for type 2 diabetes mellitus comorbid with metabolic dysfunction-associated steatotic liver disease based on routine serological indicators: a retrospective case-control study"],"prefix":"10.3389","volume":"17","author":[{"given":"Lihong","family":"Wu","sequence":"first","affiliation":[{"name":"Chaohu Hospital of Anhui Medical University","place":["Chaohu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Wang","sequence":"additional","affiliation":[{"name":"Chaohu Hospital of Anhui Medical University","place":["Chaohu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yang","sequence":"additional","affiliation":[{"name":"Chaohu Hospital of Anhui Medical University","place":["Chaohu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjun","family":"Li","sequence":"additional","affiliation":[{"name":"Chaohu Hospital of Anhui Medical University","place":["Chaohu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shui","family":"Jin","sequence":"additional","affiliation":[{"name":"Chaohu Hospital of Anhui Medical University","place":["Chaohu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000913","article-title":"Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease","volume":"83","author":"Qi","year":"2026","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5005\/jp\/books\/10445_45","article-title":"Non-alcoholic fatty liver disease and type 2 diabetes: an update","volume":"13","author":"Lee","year":"2022","journal-title":"J Diabetes Investig"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/lifemeta\/load007","article-title":"Type 2 diabetes originated from non-alcoholic fatty liver disease","volume":"2","author":"Xiong","year":"2023","journal-title":"Life Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1556\/650.2022.32479","article-title":"Non-alcoholic fatty liver disease and type 2 diabetes mellitus. I. Pathogenesis","volume":"163","author":"P\u00e1r","year":"2022","journal-title":"Orv Hetil"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12664-020-01018-x","article-title":"Epidemiology of non-alcoholic fatty liver disease in Asia","volume":"39","author":"Wong","year":"2020","journal-title":"Indian J Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2020_532","article-title":"Non-alcoholic fatty liver disease and diabetes mellitus","volume":"1307","author":"Khneizer","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14846","article-title":"Non-alcoholic fatty liver disease in type 2 diabetes - a specific entity","volume":"41","author":"Schr\u00f6der","year":"2021","journal-title":"Liver Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13258","article-title":"New perspective on type 2 diabetes, dyslipidemia and non-alcoholic fatty liver disease","volume":"11","author":"Matsuzaka","year":"2020","journal-title":"J Diabetes Investig"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.1c00104","article-title":"Serum bile acid profiles improve clinical prediction of nonalcoholic fatty liver in T2DM patients","volume":"20","author":"Wu","year":"2021","journal-title":"J Proteome Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.70112","article-title":"A nomogram incorporating clinical and laboratory indicators for predicting metabolic dysfunction-associated fatty liver disease in newly diagnosed type 2 diabetes patients","volume":"16","author":"Li","year":"2025","journal-title":"J Diabetes Investig"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1155\/grp\/2580446","article-title":"The construction and performance evaluation of a risk prediction model for nonalcoholic steatohepatitis based on serological markers","volume":"2025","author":"Huang","year":"2025","journal-title":"Gastroenterol Res Pract"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/met.2015.1502","article-title":"A perspective on metabolic syndrome and nonalcoholic fatty liver disease","volume":"13","author":"Targher","year":"2015","journal-title":"Metab Syndr Relat Disord"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2016.06.006","article-title":"Non-alcoholic fatty liver disease and risk of type 2 diabetes","volume":"30","author":"Lallukka","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.11.023","article-title":"Noninvasive assessment of hepatic steatosis","volume":"7","author":"Mazhar","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2174\/0115733998336827250114071627","article-title":"Review: Fructose, the sweet culprit behind nonalcoholic fatty liver disease and type 2 diabetes","volume":"22","author":"Otayf","year":"2026","journal-title":"Curr Diabetes Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/978-3-030-36694-0_17","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.3390\/diagnostics12102426","article-title":"A study of biomarkers associated with metabolic dysfunction-associated fatty liver disease in patients with type 2 diabetes","volume":"12","author":"Efrem","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11892-021-01383-7","article-title":"The relationship between type 2 diabetes, NAFLD, and cardiovascular risk","volume":"21","author":"Caussy","year":"2021","journal-title":"Curr Diabetes Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmab118","article-title":"Serum metabolomics in patients with coexisting NAFLD and T2DM using liquid chromatography-mass spectrometry","volume":"53","author":"Hu","year":"2022","journal-title":"Lab Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac382","article-title":"Fibrosis risk in nonalcoholic fatty liver disease is related to chronic kidney disease in older type 2 diabetes patients","volume":"107","author":"Sun","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4158\/ep-2019-0342","article-title":"Impact of type 2 diabetes on nonalcoholic steatohepatitis and advanced fibrosis in patients with nonalcoholic fatty liver disease","volume":"26","author":"Bian","year":"2020","journal-title":"Endocr Pract"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000024940","article-title":"Prevalence and risk factor analysis for the nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus","volume":"100","author":"Zhou","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2022.2058285","article-title":"Noninvasive fibrosis tools in NAFLD: validation of\u00a0APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population","volume":"134","author":"Rigor","year":"2022","journal-title":"Postgrad Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5144","DOI":"10.3390\/jcm11175144","article-title":"Nonalcoholic fatty liver disease and its complex relation with type 2 diabetes mellitus-from prevalence to diagnostic approach and treatment strategies","volume":"11","author":"Diaconu","year":"2022","journal-title":"J Clin Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence\u00a0of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12113741","article-title":"Non-alcoholic fatty liver disease and liver fibrosis in persons with type 2 diabetes mellitus in Ghana: a study of prevalence, severity, and contributing factors using transient elastography","volume":"12","author":"Wiafe","year":"2023","journal-title":"J Clin Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2025.100921","article-title":"Comparative analysis of the total proteome in nonalcoholic steatohepatitis: identification of potential biomarkers","volume":"24","author":"Ates","year":"2025","journal-title":"Mol Cell Proteomics"},{"key":"B28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.33029\/0042-8833-2025-94-5-34-41","article-title":"Hyperammonemia and metabolic-associated fatty liver disease: a complex relationship","volume":"94","author":"Deeva","year":"2025","journal-title":"Vopr Pitan"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100780","article-title":"Role of ammonia in NAFLD: an unusual suspect","volume":"5","author":"Thomsen","year":"2023","journal-title":"JHEP Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3892\/ijmm.2026.5886","article-title":"Urea cycle dysregulation and arginine pathways in the pathogenesis of NAFLD and NASH (Review)","volume":"58","author":"Zhu","year":"2026","journal-title":"Int J Mol Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1159\/000282080","article-title":"Epidemiology of non-alcoholic fatty liver disease","volume":"28","author":"Bellentani","year":"2010","journal-title":"Dig Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1038\/s41598-025-89408-z","article-title":"Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes","volume":"15","author":"Havranek","year":"2025","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2174\/157016111705190703102816","article-title":"What does the future hold for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"17","author":"Doumas","year":"2019","journal-title":"Curr Vasc Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2174\/157016112799305012","article-title":"Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options","volume":"10","author":"Tziomalos","year":"2012","journal-title":"Curr Vasc Pharmacol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1891690\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:23:04Z","timestamp":1787286184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1891690\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":34,"alternative-id":["10.3389\/fendo.2026.1891690"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1891690","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1891690"}}